Show simple item record

New business models for antibiotic innovation.

dc.contributor.author Shah, TA
dc.contributor.author So, Anthony D
dc.coverage.spatial England
dc.date.accessioned 2014-08-08T15:15:05Z
dc.date.issued 2014-05
dc.identifier http://www.ncbi.nlm.nih.gov/pubmed/24646116
dc.identifier.uri http://hdl.handle.net/10161/8997
dc.description.abstract The increase in antibiotic resistance and the dearth of novel antibiotics have become a growing concern among policy-makers. A combination of financial, scientific, and regulatory challenges poses barriers to antibiotic innovation. However, each of these three challenges provides an opportunity to develop pathways for new business models to bring novel antibiotics to market. Pull-incentives that pay for the outputs of research and development (R&D) and push-incentives that pay for the inputs of R&D can be used to increase innovation for antibiotics. Financial incentives might be structured to promote delinkage of a company's return on investment from revenues of antibiotics. This delinkage strategy might not only increase innovation, but also reinforce rational use of antibiotics. Regulatory approval, however, should not and need not compromise safety and efficacy standards to bring antibiotics with novel mechanisms of action to market. Instead regulatory agencies could encourage development of companion diagnostics, test antibiotic combinations in parallel, and pool and make transparent clinical trial data to lower R&D costs. A tax on non-human use of antibiotics might also create a disincentive for non-therapeutic use of these drugs. Finally, the new business model for antibiotic innovation should apply the 3Rs strategy for encouraging collaborative approaches to R&D in innovating novel antibiotics: sharing resources, risks, and rewards.
dc.language eng
dc.relation.ispartof Ups J Med Sci
dc.relation.isversionof 10.3109/03009734.2014.898717
dc.subject 3Rs strategy
dc.subject antibiotic innovation
dc.subject antibiotic resistance
dc.subject business models
dc.subject delinkage
dc.subject Anti-Bacterial Agents
dc.subject Models, Theoretical
dc.title New business models for antibiotic innovation.
dc.type Journal article
pubs.author-url http://www.ncbi.nlm.nih.gov/pubmed/24646116
pubs.begin-page 176
pubs.end-page 180
pubs.issue 2
pubs.organisational-group Duke
pubs.organisational-group Duke Science & Society
pubs.organisational-group Initiatives
pubs.organisational-group Institutes and Provost's Academic Units
pubs.organisational-group Sanford School of Public Policy
pubs.publication-status Published
pubs.volume 119
dc.identifier.eissn 2000-1967


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record